ADMA Biologics Investors Urged to Contact Firm Regarding Securities Fraud Lawsuit
Investors in ADMA Biologics, Inc. (NASDAQ: ADMA) are being advised by Hagens Berman to contact the law firm regarding a recently filed securities fraud class action lawsuit. The suit alleges misrepresentations concerning the company's financial condition and revenue.
PR Newswire reported on August 9, 2026, that the law firm Hagens Berman is alerting investors in ADMA Biologics, Inc. (NASDAQ: ADMA) about a securities fraud class action lawsuit that has been filed. The firm urges investors to contact them before the August 10, 2026 deadline.
The lawsuit centers on allegations that ADMA Biologics made misrepresentations regarding its financial condition and revenue. Investors who purchased ADMA Biologics stock are encouraged to reach out to Hagens Berman to learn more about their rights and the potential to recover losses.
Hagens Berman is known for representing investors in class-action lawsuits involving alleged corporate misconduct. The firm emphasizes the importance of timely action for potential class members as the deadline approaches.
No specific details about the lawsuit's claims or the company's response were provided in the initial alert. The communication serves as an invitation for affected investors to consult with the firm regarding the ongoing legal proceedings.